Literature DB >> 2109653

Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet.

B S Reddy1, J Nayini, K Tokumo, J Rigotty, E Zang, G Kelloff.   

Abstract

The effect of three levels of piroxicam and three levels of D,L-alpha-difluoromethylornithine (DFMO) fed individually and in combination during the postinitiation phase of carcinogenesis was studied in male F344 rats to generate a data base on the efficacy and synergistic and additive effects of these compounds as inhibitors of colon carcinogenesis. The maximum tolerated dose of DFMO was determined in male F344 rats and found to be 5000 ppm in the AIN-76A diet. Piroxicam at levels of 25, 75, and 150 ppm and DFMO at concentrations of 400, 1000, and 4000 ppm (20, 50, and 80% maximum tolerated dose) in AIN-76 diet were tested individually and in combinations. At 7 weeks of age, while the rats were consuming the control diet (AIN-76A), all animals except the vehicle (saline)-treated controls were given a single s.c. injection of azoxymethane (CAS: 25843-45-2) at a dose level of 29.6 mg/kg body weight to induce intestinal tumors. One week after azoxymethane injection, animals were transferred to their respective experimental diets containing piroxicam and DFMO. Fifty-six weeks after azoxymethane injection, all animals were necropsied and colon and small intestinal tumor incidences and multiplicity were compared among the various dietary groups. Feeding of diets containing 75 and 150 ppm piroxicam or 1000 and 4000 ppm DFMO significantly inhibited the incidence (percentage of animals with tumors) of colon adenocarcinomas compared to that of control diet. The multiplicity (number of tumors/rat) of adenocarcinomas was significantly inhibited in animals fed the 25, 75, and 150 ppm piroxicam or 400, 1000, and 4000 ppm DFMO diets. Results analyzed by the linear regression method suggested a dose-dependent inhibition in colon adenocarcinoma incidence with increasing levels of piroxicam or DFMO. The incidence and multiplicity of colon adenocarcinomas were significantly inhibited in animals fed the diets containing combinations of 25, 75, and 150 ppm piroxicam and 400, 1000, and 4000 ppm DFMO. Piroxicam and DFMO administered together had a stronger inhibitory effect than did those given individually. Piroxicam and DFMO when administered individually had no significant inhibitory effect on colon adenoma incidence and multiplicity; in contrast, combinations of these compounds significantly inhibited colon adenomas. No consistent differences were found in the incidence and multiplicity of small intestinal tumors among the dietary groups.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2109653

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  Effects of sulindac on sporadic colorectal adenomatous polyps.

Authors:  N Matsuhashi; A Nakajima; Y Fukushima; Y Yazaki; T Oka
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

Review 2.  Recent advances in the development of polyamine analogues as antitumor agents.

Authors:  Robert A Casero; Patrick M Woster
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

3.  Chemoprevention of DMH-induced rat colon carcinoma initiation by combination administration of piroxicam and C-phycocyanin.

Authors:  Manpreet Kaur Saini; Kim Vaiphei; Sankar Nath Sanyal
Journal:  Mol Cell Biochem       Date:  2011-10-12       Impact factor: 3.396

Review 4.  Molecular cancer prevention: Current status and future directions.

Authors:  Karen Colbert Maresso; Kenneth Y Tsai; Powel H Brown; Eva Szabo; Scott Lippman; Ernest T Hawk
Journal:  CA Cancer J Clin       Date:  2015-08-18       Impact factor: 508.702

5.  Combinatorial cytotoxic effects of Curcuma longa and Zingiber officinale on the PC-3M prostate cancer cell line.

Authors:  Kesava Rao V Kurapati; Thangavel Samikkannu; Dakshayani B Kadiyala; Saiyed M Zainulabedin; Nimisha Gandhi; Sadhana S Sathaye; Manohar A Indap; Nawal Boukli; Jose W Rodriguez; Madhavan P N Nair
Journal:  J Basic Clin Physiol Pharmacol       Date:  2012

Review 6.  Nonsteroidal anti-inflammatory drugs for the prevention of colon cancer.

Authors:  D Turner; H J Berkel
Journal:  CMAJ       Date:  1993-09-01       Impact factor: 8.262

7.  Colon carcinoma cell lines stimulate monocytes and lamina propria mononuclear cells to produce IL-10.

Authors:  T Kucharzik; N Lügering; G Winde; W Domschke; R Stoll
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

Review 8.  Targeting polyamine metabolism for cancer therapy and prevention.

Authors:  Tracy R Murray-Stewart; Patrick M Woster; Robert A Casero
Journal:  Biochem J       Date:  2016-10-01       Impact factor: 3.857

9.  Is There a Future for Chemoprevention of Prostate Cancer?

Authors:  Maarten C Bosland
Journal:  Cancer Prev Res (Phila)       Date:  2016-04-20

10.  Effect of difluoromethylornithine (DFMO) on NSAID-induced intestinal injury in rats.

Authors:  R A Erickson; N Rivera
Journal:  Dig Dis Sci       Date:  1992-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.